HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety in France?

被引：0
|
作者：
Ativon, F. [1 ]
Lebeller, C. [2 ]
Schiestel, T. [3 ]
Grandvuillemin, A. [4 ]
Davani, S. [1 ]
Valnet-Rabier, M. B. [1 ]
机构：
[1] Ctr Reg Pharmacovigilance Franche Comte, Besancon, France
[2] Ctr Reg Pharmacovigilance Paris, HEGP, Paris, France
[3] Ctr Reg Pharmacovigilance Paris Fernand Widal, Paris, France
[4] Ctr Reg Pharmacovigilance Bourgogne, Dijon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷
关键词：
HIV PrEP; TDF/emtricitabine; safety;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-117
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [31] Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients
    Gazzard, BG
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (06) : 793 - 802
  • [32] LC Assay for a HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate and Rilpivirine
    Murali Pendela
    Getu Weldu Kahsay
    Guy Van den Mooter
    Lieven Baert
    Jos Hoogmartens
    Erwin Adams
    Chromatographia, 2011, 73 : 439 - 445
  • [33] First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine
    Siguier, M.
    Mera, R.
    Pialoux, G.
    Ohayon, M.
    Cotte, L.
    Valin, N.
    Ghosn, J.
    Cua, E.
    Pintado, C.
    Chas, J.
    Barriere, G.
    Durand, F.
    Molina, J. M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) : 2752 - 2758
  • [34] Emtricitabine/tenofovir-disoproxil-fumarate/raltegravirLack of efficacy
    Reactions Weekly, 2024, 2016 (1) : 182 - 182
  • [35] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Inès Devred
    Kick Kayembe
    Nadia Valin
    Hayette Rougier
    Bruce Wuembulua Shinga
    Sidonie Lambert-Niclot
    Thibault Chiarabini
    Marie-Caroline Meyohas
    Karine Lacombe
    BMC Infectious Diseases, 23
  • [36] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Devred, Ines
    Kayembe, Kick
    Valin, Nadia
    Rougier, Hayette
    Shinga, Bruce Wuembulua
    Lambert-Niclot, Sidonie
    Chiarabini, Thibault
    Meyohas, Marie-Caroline
    Lacombe, Karine
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [37] Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals
    Jotwani, Vasantha
    Scherzer, Rebecca
    Glidden, David V.
    Mehrotra, Megha
    Defechereux, Patricia
    Liu, Albert
    Gandhi, Monica
    Bennett, Michael
    Coca, Steven G.
    Parikh, Chirag R.
    Grant, Robert M.
    Shlipak, Michael G.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (02) : 169 - 174
  • [38] Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre- exposure prophylaxis
    Solomon, Marc M.
    Lama, Javier R.
    Glidden, David V.
    Mulligan, Kathleen
    McMahan, Vanessa
    Liu, Albert Y.
    Vicente Guanira, Juan
    Veloso, Valdilea G.
    Mayer, Kenneth H.
    Chariyalertsak, Suwat
    Schechter, Mauro
    Bekker, Linda-Gail
    Kallas, Esper Georges
    Burns, David N.
    Grant, Robert M.
    AIDS, 2014, 28 (06) : 851 - 859
  • [39] Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities
    Girometti, Nicolo
    Jones, Rachael
    Levy, Jeremy
    McCormack, Sheena
    Sullivan, Ann
    Barber, Tristan J.
    AIDS, 2016, 30 (13) : 2131 - 2133
  • [40] Elvitegravir/emtricitabine/tenofovir-disoproxil-fumarate/cobicistat/emtricitabine/tenofovir-disoproxil-fumarateCluster headache: case report
    Reactions Weekly, 2024, 2033 (1) : 105 - 105
12345